Published in PLoS One on January 11, 2012
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav (2014) 1.93
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A (2013) 1.76
Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS (2012) 1.55
Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV AIDS (Auckl) (2015) 1.31
Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One (2013) 1.17
Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men. AIDS Behav (2015) 1.13
Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS One (2013) 1.03
Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. AIDS (2014) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open (2012) 1.01
Attitudes and perceptions of biomedical HIV prevention methods: voices from young men who have sex with men. Arch Sex Behav (2015) 1.00
Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS One (2014) 0.97
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses (2013) 0.95
Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations. AIDS Res Hum Retroviruses (2013) 0.95
Emerging themes for sensitivity training modules of African healthcare workers attending to men who have sex with men: a systematic review. Int Health (2015) 0.95
Knowledge of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men in Denver, Colorado. AIDS Behav (2014) 0.94
Tailored combination prevention packages and PrEP for young key populations. J Int AIDS Soc (2015) 0.93
Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retroviruses (2014) 0.92
Interventions to address HIV and intimate partner violence in Sub-Saharan Africa: a review of the literature. J Assoc Nurses AIDS Care (2013) 0.91
Opportunities for HIV combination prevention to reduce racial and ethnic health disparities. Am Psychol (2013) 0.90
Acceptability of HIV Pre-exposure Prophylaxis (PREP) Among People Who Inject Drugs (PWID) in a Canadian Setting. AIDS Behav (2015) 0.89
Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. J Int AIDS Soc (2015) 0.88
Acceptability of Condoms, Circumcision and PrEP among Young Black Men Who Have Sex with Men: A Descriptive Study Based on Effectiveness and Cost. Vaccines (Basel) (2014) 0.86
Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches. Curr HIV/AIDS Rep (2014) 0.86
Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. J AIDS Clin Res (2012) 0.86
Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85
Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDS (2014) 0.85
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. Drug Deliv Transl Res (2017) 0.82
The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers. Afr J Reprod Health (2014) 0.82
High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One (2014) 0.82
"How I Wish This Thing Was Initiated 100 Years Ago!" Willingness to Take Daily Oral Pre-Exposure Prophylaxis among Men Who Have Sex with Men in Kenya. PLoS One (2016) 0.82
HIV pre-exposure prophylaxis interest among female sex workers in Guangxi, China. PLoS One (2014) 0.82
Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). AIDS Behav (2016) 0.82
HIV-Negative Partnered Men's Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples. LGBT Health (2015) 0.82
PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers. J Int AIDS Soc (2016) 0.82
HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc (2014) 0.81
Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. Curr Treat Options Infect Dis (2015) 0.81
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. AIDS Behav (2016) 0.81
Prevalence and characteristics of users of pre-exposure prophylaxis (PrEP) among men who have sex with men, San Francisco, 2014 in a cross-sectional survey: implications for disparities. Sex Transm Infect (2016) 0.81
'PrEP is not ready for our community, and our community is not ready for PrEP': pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response. Addiction (2016) 0.78
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother (2016) 0.78
Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav (2016) 0.78
Sexual Behavior Patterns and PrEP Dosing Preferences in a Large Sample of North American Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2016) 0.77
Explaining the Efficacy of Pre-exposure Prophylaxis (PrEP) for HIV Prevention: A Qualitative Study of Message Framing and Messaging Preferences Among US Men Who have Sex with Men. AIDS Behav (2016) 0.77
Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions. Bull Math Biol (2013) 0.77
Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. AIDS Care (2017) 0.77
Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend (2017) 0.76
Potential impact of pre-exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study. J Int AIDS Soc (2016) 0.75
Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study. J Int AIDS Soc (2014) 0.75
Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. J Int AIDS Soc (2016) 0.75
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS (2017) 0.75
Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis. Sex Transm Dis (2016) 0.75
Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med (2003) 6.67
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
Structural barriers and facilitators in HIV prevention: a review of international research. AIDS (2000) 4.53
Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess (2001) 4.31
Health systems and access to antiretroviral drugs for HIV in Southern Africa: service delivery and human resources challenges. Reprod Health Matters (2006) 4.15
Methods to reduce social desirability bias in sex surveys in low-development settings: experience in Zimbabwe. Sex Transm Dis (2002) 3.34
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75
A comparison of HIV stigma and discrimination in five international sites: the influence of care and treatment resources in high prevalence settings. Soc Sci Med (2009) 2.22
Making HIV prevention programmes work. Lancet (2008) 2.22
Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS (2011) 2.15
Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol (1997) 2.13
Pre-exposure prophylaxis for HIV infection: what if it works? Lancet (2007) 2.07
Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care (2008) 2.01
Assessment of self-reported sexual behavior and condom use among female sex workers in India using a polling box approach: a preliminary report. Sex Transm Dis (2008) 1.95
Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr (2006) 1.93
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going? J Womens Health Gend Based Med (2001) 1.84
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS (2011) 1.60
Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr (2007) 1.46
Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy (2003) 1.45
Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep (2011) 1.24
Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol (2011) 1.23
Creating access to health technologies in poor countries. Health Aff (Millwood) (2009) 1.23
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS (2011) 1.22
Expanding the space: inclusion of most-at-risk populations in HIV prevention, treatment, and care services. J Acquir Immune Defic Syndr (2011) 1.19
Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health (Larchmt) (2010) 1.14
A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect (2010) 1.06
HIV prevention trial in women is abandoned after drugs show no impact on infection rates. BMJ (2011) 0.85
Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm. BMJ (2011) 0.80
Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet (2002) 7.64
HIV decline associated with behavior change in eastern Zimbabwe. Science (2006) 6.98
Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet (2011) 5.58
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62
Host immunity and synchronized epidemics of syphilis across the United States. Nature (2005) 3.34
Effects of unconditional and conditional cash transfers on child health and development in Zimbabwe: a cluster-randomised trial. Lancet (2013) 2.98
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
A systematic review and meta-analysis of quantitative interviewing tools to investigate self-reported HIV and STI associated behaviours in low- and middle-income countries. Int J Epidemiol (2010) 2.59
Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med (2007) 2.56
Prevalence, awareness, treatment and control of hypertension among slum dwellers in Nairobi, Kenya. J Hypertens (2013) 2.32
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav (2011) 1.95
Handheld computers for self-administered sensitive data collection: a comparative study in Peru. BMC Med Inform Decis Mak (2008) 1.82
Beer halls as a focus for HIV prevention activities in rural Zimbabwe. Sex Transm Dis (2005) 1.72
Engaging men in prevention and care for HIV/AIDS in Africa. PLoS Med (2012) 1.71
Patterns of movement and risk of HIV infection in rural Zimbabwe. J Infect Dis (2005) 1.62
Critique of early models of the demographic impact of HIV/AIDS in sub-Saharan Africa based on contemporary empirical data from Zimbabwe. Proc Natl Acad Sci U S A (2007) 1.58
Sex with stitches: assessing the resumption of sexual activity during the postcircumcision wound-healing period. AIDS (2012) 1.54
The future of the HIV pandemic. Bull World Health Organ (2005) 1.50
How the Avahan HIV prevention program transitioned from the Gates Foundation to the government of India. Health Aff (Millwood) (2013) 1.50
Patterns of self-reported behaviour change associated with receiving voluntary counselling and testing in a longitudinal study from Manicaland, Zimbabwe. AIDS Behav (2009) 1.41
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Early antenatal care: does it make a difference to outcomes of pregnancy associated with syphilis? A systematic review and meta-analysis. PLoS One (2013) 1.28
Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine (2006) 1.20
The epidemiological and control implications of HIV transmission probabilities within partnerships. Sex Transm Dis (2002) 1.17
Measuring and correcting biased child mortality statistics in countries with generalized epidemics of HIV infection. Bull World Health Organ (2010) 1.17
Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One (2013) 1.17
The cost-effectiveness of syndromic management in pharmacies in Lima, Peru. Sex Transm Dis (2003) 1.15
The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS (2013) 1.14
Understanding the modes of transmission model of new HIV infection and its use in prevention planning. Bull World Health Organ (2012) 1.14
Patterns of uptake of HIV testing in sub-Saharan Africa in the pre-treatment era. Trop Med Int Health (2012) 1.10
Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria. J Hypertens (2015) 1.04
Chronic kidney disease: a new priority for primary care. Br J Gen Pract (2006) 1.03
Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open (2012) 1.01
Evaluating the proximate determinants framework for HIV infection in rural Zimbabwe. Sex Transm Infect (2007) 1.00
Increasing adolescent HIV prevalence in Eastern Zimbabwe--evidence of long-term survivors of mother-to-child transmission? PLoS One (2013) 0.96
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine (2006) 0.94
Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine (2006) 0.92
The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: are we ready to infer poor adherence? J Acquir Immune Defic Syndr (2012) 0.91
Did national HIV prevention programs contribute to HIV decline in Eastern Zimbabwe? Evidence from a prospective community survey. Sex Transm Dis (2011) 0.90
Do support groups members disclose less to their partners? The dynamics of HIV disclosure in four African countries. BMC Public Health (2013) 0.90
A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One (2010) 0.89
Monitoring trends in HIV prevalence among young people, aged 15 to 24 years, in Manicaland, Zimbabwe. J Int AIDS Soc (2011) 0.88
Introducing a model of cardiovascular prevention in Nairobi's slums by integrating a public health and private-sector approach: the SCALE-UP study. Glob Health Action (2013) 0.86
Suppressive valacyclovir therapy: impact on the population spread of HSV-2 infection. Sex Transm Dis (2007) 0.86
Self-medication prevalence for sexually transmitted diseases: meta-analysis and meta-regression of population level determinants. Sex Transm Dis (2009) 0.85
Introduction to recent developments in HIV epidemic modeling. Curr Opin HIV AIDS (2011) 0.84
Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. AIDS (2006) 0.82
Measuring safety and efficiency in the operating room: development and validation of a metric for evaluating task execution in the operating room. J Am Coll Surg (2013) 0.82
Could better tolerated HIV drug regimens improve patient outcome? AIDS (2012) 0.79
Superinfection with a heterologous HIV strain per se does not lead to faster progression. Math Biosci (2009) 0.79
Building global capacity for patient safety: a training program for surgical safety research in developing and transitional countries. Int J Surg (2012) 0.79
Studying complex interactions among determinants of healthcare-seeking behaviours: self-medication for sexually transmitted infection symptoms in female sex workers. Sex Transm Infect (2010) 0.77
Promising control of genital warts: but is elimination possible? Lancet Infect Dis (2011) 0.76
Condom use by female sex workers and their clients in Mexico: who decides and does it matter? Sex Transm Infect (2011) 0.76
U.K. immigrant screening is inversely related to regional tuberculosis burden. Thorax (2011) 0.75
Antiretroviral treatment is a behavioural intervention: but why? AIDS (2010) 0.75